afatinib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Mechanism: Epidermal growth factor receptor erbB1 inhibitor.
- Mechanism
- Epidermal growth factor receptor erbB1 inhibitor
biotech · Metastatic Non-Small Cell Lung Cancer · NSCLC · AVBP
ArriVent BioPharma
ArriVent BioPharma drug portfolio — 4 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Newtown Square, USA HQ
75 Employees
Public company Type
AVBP · NYSE Ticker
Company details
- Status
- Public
- HQ
- Newtown Square, USA
- Employees
- 75
- Programs
- 7
- Drugs
- 4
- Patents
- 0
ArriVent BioPharma pipeline
Portfolio lens on 4 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
ArriVent BioPharma drug portfolio — 4 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to ArriVent BioPharma in public FDA and regional records.
-
Development asset linked to ArriVent BioPharma in public FDA and regional records. Molecular target: Epidermal growth factor receptor.
- Target
- Epidermal growth factor receptor
- Mechanism
- Epidermal growth factor receptor erbB1 inhibitor
-
osimertinib
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in ArriVent BioPharma's portfolio. Molecular target: Epidermal growth factor receptor.
- Target
- Epidermal growth factor receptor
- Mechanism
- Epidermal growth factor receptor erbB1 inhibitor